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Background
PBMC assays are plagued with significant variability in
neutralization titers due to leukopak differences. Here we
assess PBMC surface phenotypes, genotypes and viral per-
missivity to identify leukopak characteristics that correlate
with optimal performance in neutralization assays, as part
of a standardization program.
Methods
Leukopaks (N = 51) were analyzed using multi-parametric
flow cytometry (LSRII cytometer, Becton Dickinson) to
quantitate immune cell populations and surface markers.
Viral titrations were performed using infectious molecular
clones (IMC) (293T cell-derived or PBMC-passaged) and
IC50 values were calculated using the Spearman-Karber
formula. Productive replication in leukopaks was ana-
lyzed by p24 or luciferase expression; phenotypic corre-
lates of viral permissiveness were assessed by Spearman
correlation analyses.
Results
Leukopaks were rank ordered using titrations of a panel of
6 IMC, and permissive versus resistant leukopaks were
identified. Eight leukopaks from one donor showed a
wide range in permissivity. As expected, permissive leuko-
paks showed higher CD4+ T cells (median = 50.7%),
compared with more resistant leukopaks (median =
36.9%), and the converse was observed for CD8+T cells.
Unexpectedly, permissive donors had fewer CCR5+CD4+
T cells (median = 5.8%), as compared with less permissive
(median = 11.1%). Several surface markers (ie. CD38,
CD69, HLA-DR and CXCR4) showed no difference
between groups. For 2 reporter IMCs tested, titers corre-
lated well for 293T-derived and PBMC passaged virus (NL
LucR.T2A-SF162.ecto, p = 0.042; NL LucR.T2A BaL.ecto, p
= 0.0006), suggesting utility of 293T stocks.
Conclusion
Use of CD8-depleted versus bulk PBMC for HIV neutrali-
zation may be warranted, as %CD4+ and %CD8+ T cells
post-PHA stimulation was clearly associated with leuko-
pak permissiveness. PBMC pooling may provide an
option to overcome the within and between donor varia-
tion. No other phenotypic or genetic characteristics have
as yet been associated with leukopak performance in viral
assays; numerous analyses are ongoing. Regarding viral
growth, use of 293T-derived IMCs may be warranted;
studies comparing HIV neutralization titers using both
sources will further inform this.
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